To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy

Recruiting now · Phase 4

Conditions studied: Transthyretin Amyloid Polyneuropathy

In brief

The purpose of this study is to evaluate the efficacy and safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients with Transthyretin Amyloid Polyneuropathy

Key facts

Study ID

NCT06940336

Run by

Qilu Pharmaceutical Co., Ltd.

People needed

15

Starts

2025-06-19

Expected to finish

2028-02-01

Last updated by the study team

2025-07-30

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female participants between the ages of 18 and 80 years.
• Participant has amyloid deposits confirmed by biopsy (Biopsy must have been performed within 5 years prior to enrollment).
• Participant must have a TTR mutation that is associated with ATTR-PN (TTR mutation test must have been performed within 5 years prior to enrollment).
• Participant has peripheral neuropathy at screening.
• Participant has a Karnofsky Performance Status Score ≥50.
• Stages of disease according to symptom severity-stage 1.

You may not qualify if…

• Participant has other causes of amyloidosis, such as light chain amyloidosis, AA amyloidosis.
• Participant has used tafamidis within 2 months prior to enrollment.
• Participant has used diflunisal, patisiran, inotersen, or other agents for familial amyloidosis within 30 days prior to enrollment or plan to use them during the study period.
• Participant has used non-protocol NSAIDs more than 4 times within 30 days prior to enrollment or plan to use them more than 4 times per month during the study period.
• Participant has used doxycycline,tauroursodeoxycholate within 14 days prior to enrollment or plan to use them during the study period.
• Participant has sensory motor neuropathy caused by other causes, such as chronic inflammatory demyelinating polyradiculopathy, chronic idiopathic axonal neuropathy, diabetic neuropathy, chronic alcoholic neuropathy, paraneoplastic neuropathy,Guillain-Barre syndrome, vitamin B12 deficiency.
• Participant has received liver or any other organ except cornea transplantation.

Where it is running

• Qilu Hospital of Shandong University — Jinan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.